Kenta Biotech AG

Kenta Biotech is pioneering the use of fully human antibodies to fight life-threatening hospital infections. Kenta Biotech is a private company founded in 2006 and is headquartered in Berne, Switzerland.

Kenta’s pipeline includes a series of 7 genuinely human antibodies to target the most difficult to treat pathogens causing life-threatening hospital infections, such as P. aeruginosa, S. aureus and A. baumannii. Kenta Biotech's antibodies are intended as life-saving treatments for the most vulnerable patients in intensive care units.

Kenta’s first-in-class, targeted therapies have the potential to revolutionise the treatment of hospital infections, to reduce mortality and to shorten hospital stays.

Kenta is the first company to use genuinely human antibodies as they were intended by nature – to fight infection.